Top

Published in:

Open Access 01-03-2022 | Herpes Virus | Original Article

Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus

Authors: Larissa Henze, Christoph Buhl, Michael Sandherr, Oliver A. Cornely, Werner J. Heinz, Yascha Khodamoradi, Til Ramon Kiderlen, Philipp Koehler, Alrun Seidler, Rosanne Sprute, Martin Schmidt-Hieber, Marie von Lilienfeld-Toal

Published in: Annals of Hematology | Issue 3/2022

Abstract

Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy and as herpes zoster in patients with lymphoma or multiple myeloma. In recent years, knowledge on reactivation rates and clinical manifestations has increased for conventional chemotherapeutics as well as for many new antineoplastic agents. This guideline summarizes current evidence on herpesvirus reactivation in patients with solid tumours and hematological malignancies not undergoing allogeneic or autologous hematopoietic stem cell transplantation or other cellular therapy including diagnostic, prophylactic, and therapeutic aspects. Particularly, strategies of risk adapted pharmacological prophylaxis and vaccination are outlined for different patient groups. This guideline updates the guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) from 2015 “Antiviral prophylaxis in patients with solid tumours and haematological malignancies” focusing on herpes simplex virus and varicella zoster virus.

Chen S-Y, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S et al (2014) Incidence of herpes zoster in patients with altered immune function. Infection 42(2):325–334. https://doi.org/10.1007/s15010-013-0550-8CrossRefPubMed

Ruiz-Camps I, Aguilar-Company J (2021) Risk of infection associated with targeted therapies for solid organ and hematological malignancies. Ther Adv Infect Dis 8:2049936121989548. https://doi.org/10.1177/2049936121989548CrossRefPubMedPubMedCentral

Teh BW, Harrison SJ, Worth LJ, Thursky KA, Slavin MA (2016) Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis. Eur J Cancer 67:21–37. https://doi.org/10.1016/j.ejca.2016.07.025CrossRefPubMed

Lee HS, Park JY, Shin SH, Kim SB, Lee JS, Lee A et al (2012) Herpesviridae viral infections after chemotherapy without antiviral prophylaxis in patients with malignant lymphoma: incidence and risk factors. Am J Clin Oncol 35(2):146–150. https://doi.org/10.1097/COC.0b013e318209aa41CrossRefPubMed

Tan IL, McArthur JC, Venkatesan A, Nath A (2012) Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology 79(21):2125–2132. https://doi.org/10.1212/WNL.0b013e3182752cebCrossRefPubMedPubMedCentral

Styczynski J (2021) Management of herpesvirus infections in hematopoietic cell transplant recipients. Transplantology 2(1):8–21. https://doi.org/10.3390/transplantology2010002CrossRef

Beyar-Katz O, Bitterman R, Zuckerman T, Ofran Y, Yahav D, Paul M (2020) Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis. Clin Microbiol Infect 26(2):189–198. https://doi.org/10.1016/j.cmi.2019.09.003CrossRefPubMed

Christopeit M, Schmidt-Hieber M, Sprute R, Buchheidt D, Hentrich M, Karthaus M et al (2020) Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 100(2):321–36. https://doi.org/10.1007/s00277-020-04297-8CrossRefPubMedPubMedCentral

Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O et al (2015) Antiviral prophylaxis in patients with solid tumours and haematological malignancies–update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol 94(9):1441–1450. https://doi.org/10.1007/s00277-015-2447-3CrossRefPubMedPubMedCentral

10.

Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S et al (2012) ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 18(Suppl 7):53–67. https://doi.org/10.1111/1469-0691.12041CrossRefPubMed

11.

Levin MJ, Weinberg A, Schmid DS (2016) Herpes simplex virus and varicella-zoster virus. Microbiol Spectrum 4(3):2015. https://doi.org/10.1128/microbiolspec.DMIH2-0017-2015CrossRef

12.

Glenny A-M, Fernandez Mauleffinch LM, Pavitt S, Walsh T (2009) Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev 1:CD006706. https://doi.org/10.1002/14651858.CD006706.pub2CrossRef

13.

Herget GW, Riede UN, Schmitt-Gräff A, Lübbert M, Neumann-Haefelin D, Köhler G (2005) Generalized herpes simplex virus infection in an immunocompromised patient–report of a case and review of the literature. Pathol Res Pract 201(2):123–129. https://doi.org/10.1016/j.prp.2004.12.003CrossRefPubMed

14.

Djuric M, Jankovic L, Jovanovic T, Pavlica D, Brkic S, Knezevic A et al (2009) Prevalence of oral herpes simplex virus reactivation in cancer patients: a comparison of different techniques of viral detection. J Oral Pathol Med 38(2):167–173. https://doi.org/10.1111/j.1600-0714.2008.00684.xCrossRefPubMed

15.

Spruance SL, Bodsworth N, Resnick H, Conant M, Oeuvray C, Gao J et al (2006) Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol 55(1):47–53. https://doi.org/10.1016/j.jaad.2006.02.031CrossRefPubMed

16.

Christman MP, Turbett SE, Sengupta S, Bakhadirov KU, Williamson CA, Nayak L et al (2014) Recurrence of herpes simplex encephalitis associated with temozolomide chemoradiation for malignant glioma: a case report and review of the literature. Oxf Med Case Reports 2014(1):1–4. https://doi.org/10.1093/omcr/omu001CrossRefPubMedPubMedCentral

17.

Graber JJ, Rosenblum MK, DeAngelis LM (2011) Herpes simplex encephalitis in patients with cancer. J Neurooncol 105(2):415–421. https://doi.org/10.1007/s11060-011-0609-2CrossRefPubMed

18.

Toomey DP, Dhadda AS, Sanni LA, Cooke JP, Hartley JE (2014) Fatal herpes simplex virus hepatitis following neoadjuvant chemoradiotherapy and anterior resection for rectal cancer. Ann R Coll Surg Engl 96(8):e12–e14. https://doi.org/10.1308/003588414X13946184902721CrossRefPubMedPubMedCentral

19.

Patel R, Kennedy OJ, Clarke E, Geretti A, Nilsen A, Lautenschlager S et al (2017) 2017 European guidelines for the management of genital herpes. Int J STD AIDS 28(14):1366–1379. https://doi.org/10.1177/0956462417727194CrossRefPubMed

20.

Hong J, Park H-K, Park S, Lee A, Lee Y-H, Shin D-Y et al (2020) Strong association between herpes simplex virus-1 and chemotherapy-induced oral mucositis in patients with hematologic malignancies. Korean J Intern Med 35(5):1188–1198. https://doi.org/10.3904/kjim.2018.469CrossRefPubMed

21.

Whitley RJ, Kimberlin DW, Roizman B (1998) Herpes simplex viruses. Clin Infect Diseases 26:541–555CrossRef

22.

Le Cleach L, Trinquart L, Do G, Maruani A, Lebrun-Vignes B, Ravaud P et al (2014) Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Cochrane Database Syst Rev 8:CD009036. https://doi.org/10.1002/14651858.CD009036.pub2CrossRef

23.

Gupta R, Wald A, Krantz E, Selke S, Warren T, Vargas-Cortes M et al (2004) Valacyclovir and Acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 190(8):1374–1381CrossRefPubMed

24.

Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D et al (2015) Varicella zoster virus infection. Nat Rev Dis Primers 1:15016–15034. https://doi.org/10.1038/nrdp.2015.16CrossRefPubMedPubMedCentral

25.

Andrei G, Snoeck R (2021) Advances and perspectives in the management of varicella-zoster virus infections. Molecules 26(4):1132. https://doi.org/10.3390/molecules26041132CrossRefPubMedPubMedCentral

26.

Dagnew AF, Ilhan O, Lee W-S, Woszczyk D, Kwak J-Y, Bowcock S et al (2019) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis 19(9):988–1000. https://doi.org/10.1016/S1473-3099(19)30163-XCrossRefPubMed

27.

Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372(22):2087–2096. https://doi.org/10.1056/NEJMoa1501184CrossRefPubMed

28.

Habel LA, Ray GT, Silverberg MJ, Horberg MA, Yawn BP, Castillo AL et al (2013) The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiol Biomarkers Prev 22(1):82–90. https://doi.org/10.1158/1055-9965.EPI-12-0815CrossRefPubMed

29.

Williams AM, Baran AM, Meacham PJ, Feldman MM, Valencia HE, Newsom-Stewart C et al (2018) Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies. Leuk Lymphoma 59(3):625–632. https://doi.org/10.1080/10428194.2017.1347931CrossRefPubMed

30.

van der Beek MT, Vermont CL, Bredius RGM, Marijt EWA, van der Blij-de Brouwer CS, Kroes ACM et al (2013) Persistence and antiviral resistance of varicella zoster virus in hematological patients. Clin Infect Diseases 56(3):335–343. https://doi.org/10.1093/cid/cis879CrossRef

31.

Giridhar KV, Shanafelt T, Tosh PK, Parikh SA, Call TG (2017) Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors. Leuk Lymphoma 58(8):1973–1976. https://doi.org/10.1080/10428194.2016.1267352CrossRefPubMed

32.

Sutton E, Lopez JJ, Dao LN, Wetter DA (2016) Disseminated herpes zoster in chronic lymphocytic leukemia. J Emerg Med 50(3):e159–e160. https://doi.org/10.1016/j.jemermed.2015.10.035CrossRefPubMed

33.

Yahav D, Gafter-Gvili A, Muchtar E, Skalsky K, Kariv G, Yeshurun M et al (2009) Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. Euro J Cancer 45(18):3131–48. https://doi.org/10.1016/j.ejca.2009.08.010CrossRef

34.

Elad S, Ranna V, Ariyawardana A, Correa MEP, Tilly V, Nair RG et al (2017) A systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventions. Support Care Cancer 25(2):687–700. https://doi.org/10.1007/s00520-016-3477-7CrossRefPubMed

35.

Angarone M (2011) Epidemiology and prevention of viral infections in patients with hematologic malignancies. Infect Disord Drug Targets 11(1):27–33CrossRefPubMed

36.

Aribi Al-Zoobaee FW, Yee SL, Veettil SK, Gopinath D, Maharajan MK, Menon RK (2020) Antiviral agents for the prevention and treatment of herpes simplex virus type-1 infection in clinical oncology: a network meta-analysis. Int J Environ Res Public Health 17(23):8891. https://doi.org/10.3390/ijerph17238891CrossRefPubMedCentral

37.

Taplitz RA, Kennedy Erin B, Bow Eric J, Crews J, Gleason C, Hawley DK et al (2018) Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol 36:3043–3054. https://doi.org/10.1200/JCO.18.00374CrossRefPubMed

38.

Koordinatorin: Schmidt B. Virusinfektionen bei Organ- und allogen Stammzell-Transplantierten: Diagnostik, Prävention und Therapie: S2k-Leitlinie. AWMF Registernummer 093–002. [November 30, 2020]; Available from: https://www.awmf.org/leitlinien/detail/ll/093-002.html.

39.

Wald A, Huang ML, Carrell D, Selke S, Corey L (2003) Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis 188(9):1345–1351. https://doi.org/10.1086/379043CrossRefPubMed

40.

Levin MJ (2014) Varicella-zoster virus and virus DNA in the blood and oropharynx of people with latent or active varicella-zoster virus infections. J Clin Virol 61(4):487–495. https://doi.org/10.1016/j.jcv.2014.09.012CrossRefPubMed

41.

Wilson DA, Yen-Lieberman B, Schindler S, Asamoto K, Schold JD, Procop GW (2012) Should varicella-zoster virus culture be eliminated? A comparison of direct immunofluorescence antigen detection, culture, and PCR, with a historical review. J Clin Microbiol 50(12):4120–4122. https://doi.org/10.1128/JCM.06753-11CrossRefPubMedPubMedCentral

42.

Bhullar SS, Chandak NH, Purohit HJ, Taori GM, Daginawala HF, Kashyap RS (2014) Determination of viral load by quantitative real-time PCR in herpes simplex encephalitis patients. Intervirology 57(1):1–7. https://doi.org/10.1159/000351521CrossRefPubMed

43.

van der Beek MT, Laheij AMGA, Raber-Durlacher JE, von dem Borne PA, Wolterbeek R, van der Blij-de Brouwer CS et al (2012) Viral loads and antiviral resistance of herpesviruses and oral ulcerations in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 47(9):1222–1228. https://doi.org/10.1038/bmt.2012.2CrossRefPubMed

44.

Sauerbrei A (2016) Herpes genitalis: diagnosis, treatment and prevention. Geburtshilfe Frauenheilkd 76(12):1310–1317. https://doi.org/10.1055/s-0042-116494CrossRefPubMedPubMedCentral

45.

Park SY, Kim JY, Kim J-A, Kwon J-S, Kim S-M, Jeon NY et al (2017) Diagnostic usefulness of varicella-zoster virus real-time polymerase chain reaction analysis of DNA in saliva and plasma specimens from patients with herpes zoster. J INFECT DIS 217(1):51–57. https://doi.org/10.1093/infdis/jix508CrossRefPubMed

46.

Gershon AA (2011) The history and mystery of VZV in saliva. J INFECT DIS 204(6):815–816. https://doi.org/10.1093/infdis/jir417CrossRefPubMedPubMedCentral

47.

Ramchandani M, Kong M, Tronstein E, Selke S, Mikhaylova A, Magaret A et al (2016) Herpes simplex virus type 1 shedding in tears and nasal and oral mucosa of healthy adults. Sex Transm Dis 43(12):756–760. https://doi.org/10.1097/OLQ.0000000000000522CrossRefPubMedPubMedCentral

48.

Stram MN, Suciu CN, Seheult JN, McCullough MA, Kader M, Wells A et al (2018) Herpes simplex virus-1 qPCR in the diagnosis of lower respiratory tract infections in organ transplant recipients and critically ill patients. Am J Clin Pathol 150(6):522–532. https://doi.org/10.1093/ajcp/aqy088CrossRefPubMed

49.

Schmidt-Hieber M, Silling G, Schalk E, Heinz W, Panse J, Penack O et al (2016) CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol 27(7):1207–1225. https://doi.org/10.1093/annonc/mdw155CrossRefPubMedPubMedCentral

50.

Schuierer L, Gebhard M, Ruf H-G, Jaschinski U, Berghaus TM, Wittmann M et al (2020) Impact of acyclovir use on survival of patients with ventilator-associated pneumonia and high load herpes simplex virus replication. Crit Care 24(1):12. https://doi.org/10.1186/s13054-019-2701-5CrossRefPubMedPubMedCentral

51.

Luyt C-E, Forel J-M, Hajage D, Jaber S, Cayot-Constantin S, Rimmelé T et al (2020) Acyclovir for mechanically ventilated patients with herpes simplex virus oropharyngeal reactivation: a randomized clinical trial. JAMA Intern Med 180(2):263–272. https://doi.org/10.1001/jamainternmed.2019.5713CrossRefPubMed

52.

Gross GE, Eisert L, Doerr HW, Fickenscher H, Knuf M, Maier P et al (2020) S2k-Leitlinie zur Diagnostik und Therapie des Zoster und der Postzosterneuralgie. GMS Infect Dis 8:1–31. https://doi.org/10.3205/id000045CrossRef

53.

Grahn A, Bergström T, Runesson J, Studahl M (2016) Varicella-zoster virus (VZV) DNA in serum of patients with VZV central nervous system infections. J Infect 73(3):254–260. https://doi.org/10.1016/j.jinf.2016.04.035CrossRefPubMed

54.

Mirouse A, Vignon P, Piron P, Robert R, Papazian L, Géri G et al (2017) Severe varicella-zoster virus pneumonia: a multicenter cohort study. Crit Care 21(1):137. https://doi.org/10.1186/s13054-017-1731-0CrossRefPubMedPubMedCentral

55.

Ishizaki Y, Tezuka J, Ohga S, Nomura A, Suga N, Kuromaru R et al (2003) Quantification of circulating varicella zoster virus-DNA for the early diagnosis of visceral varicella. J Infect 47(2):133–138. https://doi.org/10.1016/s0163-4453(03)00004-5CrossRefPubMed

56.

Sahoo F, Hill JA, Xie H, Leisenring W, Yi J, Goyal S et al (2017) Herpes zoster in autologous hematopoietic cell transplant recipients in the era of acyclovir or valacyclovir prophylaxis and novel treatment and maintenance therapies. Biol Blood Marrow Transplant 23(3):505–511. https://doi.org/10.1016/j.bbmt.2016.12.620CrossRefPubMed

57.

Baumrin E, Cheng MP, Kanjilal S, Ho VT, Issa NC, Baden LR (2019) Severe herpes zoster requiring intravenous antiviral treatment in allogeneic hematopoietic cell transplantation recipients on standard acyclovir prophylaxis. Biol Blood Marrow Transplant 25(8):1642–1647. https://doi.org/10.1016/j.bbmt.2019.04.015CrossRefPubMed

58.

van der Beek MT, Claas ECJ, van der Blij-de Brouwer CS, Morfin F, Rusman LG, Kroes ACM et al (2013) Rapid susceptibility testing for herpes simplex virus type 1 using real-time PCR. J Clin Virol 56(1):19–24. https://doi.org/10.1016/j.jcv.2012.09.004CrossRefPubMed

59.

Steingrimsdottir H, Gruber A, Kalin M, Eksborg S (2000) Bioavailability of aciclovir after oral administration of aciclovir and its prodrug valaciclovir to patients with leukopenia after chemotherapy. Antimicrob Agents Chemother 44(1):207–209CrossRefPubMedPubMedCentral

60.

Warkentin DI, Epstein JB, Campbell LM, Yip JG, Cox VC, Ransier A et al (2002) Valacyclovir versus acyclovir for HSV prophylaxis in neutropenic patients. Ann Pharmacother 36(10):1525–1531. https://doi.org/10.1345/aph.1A434CrossRefPubMed

61.

Lee CJ, Savani BN, Ljungman P (2018) Varicella zoster virus reactivation in adult survivors of hematopoietic cell transplantation: how do we best protect our patients? Biol Blood Marrow Transplant 24(9):1783–1787. https://doi.org/10.1016/j.bbmt.2018.04.003CrossRefPubMed

62.

San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906–917. https://doi.org/10.1056/NEJMoa0801479CrossRefPubMed

63.

Fukushima T, Sato T, Nakamura T, Iwao H, Nakajima A, Miki M et al (2012) Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib. Anticancer Res 32(12):5437–5440PubMed

64.

Usami E, Kimura M, Iwai M, Teramachi H, Yoshimura T (2016) Prophylactic efficacy against herpes zoster and costs difference between acyclovir and valaciclovir in hematological patients. In Vivo 30(5):701–705PubMed

65.

Bastidas A, de La Serna J, El Idrissi M, Oostvogels L, Quittet P, López-Jiménez J et al (2019) Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial. JAMA 322(2):123–33. https://doi.org/10.1001/jama.2019.9053CrossRefPubMedPubMedCentral

66.

Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF et al (2019) Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer 125(8):1301–1312. https://doi.org/10.1002/cncr.31909CrossRefPubMed

67.

Zent CS, Brady MT, Delage C, Strawderman M, Laniewski N, Contant PN et al (2020) Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma. Leukemia 35(6):1788–1791. https://doi.org/10.1038/s41375-020-01074-4CrossRefPubMed

68.

Pleyer C, Ali MA, Cohen JI, Tian X, Soto S, Ahn IE et al (2021) Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood 137(2):185–189. https://doi.org/10.1182/blood.2020008758CrossRefPubMed

69.

Ljungman P (2019) Varicella zoster virus vaccine in patients with haematological malignancies. Lancet Infect Dis 19(9):921–922. https://doi.org/10.1016/S1473-3099(19)30400-1CrossRefPubMed

70.

Ilyas S, Chandrasekar PH (2020) Preventing varicella-zoster: advances with the recombinant zoster vaccine. Open Forum Infect Dis 7(7):ofaa274. https://doi.org/10.1093/ofid/ofaa274CrossRefPubMedPubMedCentral

71.

Sakoh T, Kanzaki M, Miyamoto A, Mochizuki S, Kakumoto T, Sato K et al (2019) Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report. BMC Cancer 19(1):1220. https://doi.org/10.1186/s12885-019-6444-0CrossRefPubMedPubMedCentral

72.

Watanabe Y, Kikuchi R, Iwai Y, Ito M, Tsukamoto H, Yamazaki K et al (2019) Varicella zoster virus encephalitis mimicking nivolumab-induced autoimmune neuropathy in a patient with lung cancer. J Thorac Oncol 14(8):e163–e165. https://doi.org/10.1016/j.jtho.2019.02.033CrossRefPubMed

73.

Sumer J, Waldeck F, Fischer N, Appenzeller C, Koster M, Früh M et al (2021) HSV-pneumonitis in a patient with lung cancer receiving check point inhibitors — a case report. Pneumonia (Nathan) 13(1):1. https://doi.org/10.1186/s41479-020-00079-yCrossRef

74.

Del Castillo M, Romero FA, Argüello E, Kyi C, Postow MA, Redelman-Sidi G (2016) The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma. Clin Infect Dis 63(11):1490–1493. https://doi.org/10.1093/cid/ciw539CrossRefPubMedPubMedCentral

75.

Ramirez-Fort MK, Zeng J, Feily A, Ramirez-Pacheco LA, Jenrette JM, Mayhew DL et al (2018) Radiotherapy-induced reactivation of neurotrophic human herpes viruses: overview and management. J Clin Virol 98:18–27. https://doi.org/10.1016/j.jcv.2017.11.004CrossRefPubMed

76.

Malpica L, Moll S (2020) Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases. Hematol Am Soc Hematol Educ Program 2020(1):319–327. https://doi.org/10.1182/hematology.2020000116CrossRef

77.

Fardet L, Petersen I, Nazareth I (2016) Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med 13(5):e1002024. https://doi.org/10.1371/journal.pmed.1002024CrossRefPubMedPubMedCentral

78.

Anderson H, Scarffe JH, Sutton RN, Hickmott E, Brigden D, Burke C (1984) Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial. Brit J Cancer 50(1):45–9. https://doi.org/10.1038/bjc.1984.138CrossRefPubMedPubMedCentral

79.

Bergmann OJ, Ellermann-Eriksen S, Mogensesn SC, Ellegaard J (1995) Acyclovir given as prophylaxis agienst oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial. BMJ 310:1169–1172CrossRefPubMedPubMedCentral

80.

Hann IM, Prentice HG, Blacklock HA, Ross MG, Brigden D, Rosling AE et al (1983) Acyclovir prophylaxis against herpes virus infections in severly immunocompromised patients: randomised double blind trial. Br Med J (Clin REs Ed) 287:384–388CrossRef

81.

Lönnqvist B, Palmblad J, Ljungman P, Grimfors G, Järnmark M, Lerner R et al (1993) Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden. Support Care Cancer 1(3):139–44. https://doi.org/10.1007/BF00366060CrossRefPubMed

82.

Saral R, Ambinder RF, Burns WH, Angelopulos CM, Griffin DE, Burke PJ et al (1983) Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 99(6):773–6. https://doi.org/10.7326/0003-4819-99-6-773CrossRefPubMed

83.

Freyer CW, Peterson CE, Man Y, Przespolewski A, Baron J, Luger SM (2021) Herpes zoster during arsenic trioxide therapy for acute promyelocytic leukemia. Leuk Lymphoma 62(3):696–702. https://doi.org/10.1080/10428194.2020.1838507CrossRefPubMed

84.

Logan C, Koura D, Taplitz R (2020) Updates in infection risk and management in acute leukemia. Hematol Am Soc Hematol Educ Program 2020(1):135–139. https://doi.org/10.1182/hematology.2020000098CrossRef

85.

Heine A-C, Brossart P, Wolf D (2013) Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 122(23):3843–3844CrossRefPubMed

86.

Lussana F, Cattaneo M, Rambaldi A, Squizzato A (2018) Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol 93(3):339–347. https://doi.org/10.1002/ajh.24976CrossRefPubMed

87.

Gauthier N, Soret-Dulphy J, Zhao L-P, De Daltro OR, Marcault C, Parquet N et al (2020) Ruxolitinib treatment is associated with increased incidence of infections and higher risk of HSV/VZV recurrence in patients with myeloproliferative neoplasm (MPN) related myelofibrosis (MF). Blood 136(Supplement 1):8. https://doi.org/10.1182/blood-2020-141260CrossRef

88.

Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M et al (2018) Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: a multicenter study on 446 patients. Hematol Oncol 36:561–569. https://doi.org/10.1002/hon.2509CrossRef

89.

Maschmeyer G, de Greef J, Mellinghoff SC, Nosari A, Thiebaut-Bertrand A, Bergeron A, et al. (2019) Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia 33(4):844–862. https://doi.org/10.1038/s41375-019-0388-x.

90.

Park LC, Lee HS, Shin SH, Im H, Ye BJ, Song MK et al (2011) Herpesviridae viral infections following rituximab combined chemotherapy in patients with diffuse large B-cell lymphoma. Acta Haematol 125(4):230–236. https://doi.org/10.1159/000323421CrossRefPubMed

91.

Murawski N, Amam J, Altmann B, Ziepert M, Haenel M, Viardot A et al (2017) Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapyassociated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy. Oncol Res Treatment 40(Supplement 3):200

92.

Manos K, Lasica M, Grigg A, Di Ciaccio PR, Wong J, Chandra Sekaran U et al (2020) Prolonged lymphopenia and infection risk is mitigated by antimicrobial prophylaxis in patients with indolent non-hodgkin lymphoma (iNHL) treated with bendamustine +/- anti-CD20 antibody: the Australasian lymphoma alliance experience. Blood 136(Supplement 1):47–49. https://doi.org/10.1182/blood-2020-138642CrossRef

93.

Gillessen S, Plütschow A, Fuchs M, Markova J, Greil R, Topp MS et al (2021) Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14). Lancet Haematol 8(4):e278–e288. https://doi.org/10.1016/S2352-3026(21)00029-6CrossRefPubMed

94.

Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS et al (2021) PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 22(2):223–234. https://doi.org/10.1016/S1470-2045(20)30601-XCrossRefPubMed

95.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al (2018) iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131(25):2745–2760. https://doi.org/10.1182/blood-2017-09-806398CrossRefPubMed

96.

Hussaini SB, Chu J, Williams N, Sharma N, Benson Don M Jr, Rosko AE et al (2017) B-cell lymphoma patients have a 10% risk of shingles, 7% in cutaneous T-cell lymphoma. Blood 130(Supplement 1):3356. https://doi.org/10.1182/blood.V130.Suppl_1.3356.3356CrossRef

97.

Steingrímsson V, Gíslason GK, Þorsteinsdóttir S, Rögnvaldsson S, Gottfreðsson M, Aspelund T et al (2021) A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre-ibrutinib era. Eur J Haematol 106(3):346–353. https://doi.org/10.1111/ejh.13553CrossRefPubMed

98.

Allen JM, Rybicki LA, Caimi PF, Jagadeesh D, Dean RM, Pohlman B et al (2015) Standard duration of varicella zoster virus prophylaxis may be inadequate to prevent viral reactivation in patients with chronic lymphocytic leukemia treated with front-line bendamustine plus rituximab. Blood 126(23):4167. https://doi.org/10.1182/blood.V126.23.4167.4167CrossRef

99.

Srivastava R, Griswold D, Jamil MO (2018) Chronic lymphocytic leukaemia with necrotic herpetic adenitis: an elusive clinical condition. BMJ Case Rep 2018:222091. https://doi.org/10.1136/bcr-2017-222091CrossRef

100.

Oscier D, Dearden C, Eren E, Fegan C, Follows G, Hillmen P et al (2012) Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol 159(5):541–564. https://doi.org/10.1111/bjh.12067CrossRefPubMed

101.

Tillman BF, Pauff JM, Satyanarayana G, Talbott M, Warner JL (2018) Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies. Eur J Haematol 100(4):325–334. https://doi.org/10.1111/ejh.13020CrossRefPubMed

102.

Chen I, Fohtung RB, Oughli HA, Bauer R, Mattar C, Powderly WG et al (2016) Concurrent Ramsay Hunt syndrome and disseminated herpes zoster in a patient with relapsed chronic lymphocytic leukemia. IDCases 6:79–82. https://doi.org/10.1016/j.idcr.2016.10.003CrossRefPubMedPubMedCentral

103.

Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, Barrientos J et al (2019) Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 381(5):432–443. https://doi.org/10.1056/NEJMoa1817073CrossRefPubMedPubMedCentral

104.

Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L et al (2019) Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20(1):43–56. https://doi.org/10.1016/S1470-2045(18)30788-5CrossRefPubMed

105.

Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P et al (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 373(25):2425–2437. https://doi.org/10.1056/NEJMoa1509388CrossRefPubMedPubMedCentral

106.

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W et al (2018) Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 379(26):2517–2528. https://doi.org/10.1056/NEJMoa1812836CrossRefPubMedPubMedCentral

107.

Coutre SE, Byrd JC, Hillmen P, Barrientos JC, Barr PM, Devereux S et al (2019) Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Adv 3(12):1799–1807. https://doi.org/10.1182/bloodadvances.2018028761CrossRefPubMedPubMedCentral

108.

Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM et al (2014) Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371(3):213–223. https://doi.org/10.1056/NEJMoa1400376CrossRefPubMedPubMedCentral

109.

Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M et al (2019) Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 380(23):2225–2236. https://doi.org/10.1056/NEJMoa1815281CrossRefPubMed

110.

Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S et al (2018) Venetoclax- rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 378(12):1107–1120. https://doi.org/10.1056/NEJMoa1713976CrossRefPubMed

111.

Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M et al (2017) Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 18(3):297–311. https://doi.org/10.1016/S1470-2045(16)30671-4CrossRefPubMedPubMedCentral

112.

Cheah CY, Fowler NH (2016) Idelalisib in the management of lymphoma. Blood 128(3):331–336. https://doi.org/10.1182/blood-2016-02-702761CrossRefPubMedPubMedCentral

113.

Hanlon A, Brander DM (2020) Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors. Hematol Am Soc Hematol Educ Program 2020(1):346–356. https://doi.org/10.1182/hematology.2020000119CrossRef

114.

Bird ST, Tian F, Flowers N, Przepiorka D, Wang R, Jung T-H et al (2020) Idelalisib for treatment of relapsed follicular lymphoma and chronic lymphocytic leukemia: a comparison of treatment outcomes in clinical trial participants vs medicare beneficiaries. JAMA Oncol 6(2):248–254. https://doi.org/10.1001/jamaoncol.2019.3994CrossRefPubMed

115.

Sánchez-Ramón S, Dhalla F, Chapel H (2016) Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy. Front Immunol 7:317. https://doi.org/10.3389/fimmu.2016.00317CrossRefPubMedPubMedCentral

116.

Drgona L, Gudiol C, Lanini S, Salzberger B, Ippolito G, Mikulska M (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens II: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect 24(Suppl 2):S83–S94. https://doi.org/10.1016/j.cmi.2018.03.022CrossRefPubMed

117.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P et al (2018) Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 32(7):1542–1560. https://doi.org/10.1038/s41375-018-0040-1CrossRefPubMedPubMedCentral

118.

Minarik J, Pika T, Bacovsky J, Langova K, Scudla V (2012) Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. Br J Haematol 159(1):111–113. https://doi.org/10.1111/j.1365-2141.2012.09233.xCrossRefPubMed

119.

Leng S, Lentzsch S, Shen Y, Tsai W-Y, Wright JD, Hershman DL et al (2018) Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors. Leuk Lymphoma 59(10):2465–2469. https://doi.org/10.1080/10428194.2018.1429605CrossRefPubMedPubMedCentral

120.

Vickrey E, Allen S, Mehta J, Singhal S (2009) Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy. Cancer 115(1):229–232. https://doi.org/10.1002/cncr.24006CrossRefPubMed

121.

Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L et al (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621–1634. https://doi.org/10.1056/NEJMoa1516282CrossRefPubMed

122.

Muchtar E, Gertz MA, Magen H (2016) A practical review on carfilzomib in multiple myeloma. Eur J Haematol 96(6):564–577. https://doi.org/10.1111/ejh.12749CrossRefPubMed

123.

Kumar S, Moreau P, Hari P, Mateos M-V, Ludwig H, Shustik C et al (2017) Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol 178(4):571–582. https://doi.org/10.1111/bjh.14733CrossRefPubMedPubMedCentral

124.

König C, Kleber M, Reinhardt H, Knop S, Wäsch R, Engelhardt M (2014) Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients. Ann Hematol 93(3):479–484. https://doi.org/10.1007/s00277-013-1951-6CrossRefPubMed

125.

Teh BW, Harrison SJ, Worth LJ, Slavin MA (2016) Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies. Leuk Lymphoma 57(7):1719–1722. https://doi.org/10.3109/10428194.2015.1106538CrossRefPubMed

126.

Nucci M, Anaissie E (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Diseases 49(8):1211–1225. https://doi.org/10.1086/605664CrossRef

127.

Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R et al (2013) Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 98(11):1753–1761. https://doi.org/10.3324/haematol.2013.089334CrossRefPubMedPubMedCentral

128.

Nahi H, Chrobok M, Gran C, Lund J, Gruber A, Gahrton G et al (2019) Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma. PLoS ONE 14(2):e0211927. https://doi.org/10.1371/journal.pone.0211927CrossRefPubMedPubMedCentral

129.

Bergmann OJ, Mogensen SC, Ellermann-Eriksen S, Ellegaard J (1997) Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 15(6):2269–2274. https://doi.org/10.1200/JCO.1997.15.6.2269CrossRefPubMed

130.

Dang T, Ni A, Gerecitano JF Jr, Hamlin PA, Hohl TM, Kumar A et al (2016) Incidence of infectious complications associated with bendamustine and anti-CD20 monoclonal antibody combination at Memorial Sloan Kettering Cancer Center (MSKCC). Blood 128(22):1778. https://doi.org/10.1182/blood.V128.22.1778.1778CrossRef

131.

Vazquez GY, Rivera Concepcion J, Cabanillas F (2018) Incidence and risk factors for developing herpes zoster among a cohort of patients diagnosed with lymphoma at a community cancer center. Blood 132(Supplement 1):3589. https://doi.org/10.1182/blood-2018-99-113957CrossRef

132.

Stephens DM, Byrd JC (2019) How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood 133(12):1298–1307. https://doi.org/10.1182/blood-2018-11-846808CrossRefPubMedPubMedCentral

133.

Attallah J, Khan U, Sharma M, Kafri Z (2019) Disseminated herpes simplex virus type 2 after treatment with idelalisib. BJSTR 14(3):2560. https://doi.org/10.26717/BJSTR.2019.14.002560CrossRef

134.

Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau J-L et al (2008) Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 26(29):4784–4790. https://doi.org/10.1200/JCO.2007.14.9641CrossRefPubMed

135.

Pour L, Adam Z, Buresova L, Krejci M, Krivanova A, Sandecka V et al (2009) Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma 9(2):151–153. https://doi.org/10.3816/CLM.2009.n.036CrossRefPubMed

136.

Kim SJ, Kim K, Do YR, Bae SH, Yang D-H, Lee J-J (2011) Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study. Jpn J Clin Oncol 41(3):353–357. https://doi.org/10.1093/jjco/hyq194CrossRefPubMed

137.

Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D et al (2012) Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol 10(4):155–159. https://doi.org/10.1016/j.suponc.2011.10.006CrossRefPubMed

138.

Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M et al (2018) Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 379(19):1811–1822. https://doi.org/10.1056/NEJMoa1805762CrossRefPubMed

139.

Nikkels AF, Piérard GE (2002) Oral antivirals revisited in the treatment of herpes zoster: what do they accomplish? Am J Clin Dermatol 3(9):591–598. https://doi.org/10.2165/00128071-200203090-00001CrossRefPubMed

140.

Werner RN, Nikkels AF, Marinović B, Schäfer M, Czarnecka-Operacz M, Agius AM et al (2017) European consensus-based (S2k) guideline on the management of herpes zoster — guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J Eur Acad Dermatol Venereol 31(1):20–29. https://doi.org/10.1111/jdv.13957CrossRefPubMed

141.

Bradshaw MJ, Venkatesan A (2016) Herpes simplex virus-1 encephalitis in adults: pathophysiology, diagnosis, and management. Neurotherapeutics 13(3):493–508. https://doi.org/10.1007/s13311-016-0433-7CrossRefPubMedPubMedCentral

142.

Kalezic T, Mazen M, Kuklinski E, Asbell P (2018) Herpetic eye disease study: lessons learned. Curr Opin Ophthalmol 29(4):340–346. https://doi.org/10.1097/ICU.0000000000000482CrossRefPubMed

143.

Li JY (2018) Herpes zoster ophthalmicus: acute keratitis. Curr Opin Ophthalmol 29(4):328–333. https://doi.org/10.1097/ICU.0000000000000491CrossRefPubMed

144.

Rätz Bravo AE, Hofer S, Krähenbühl S, Ludwig C (2009) Fatal drug-drug interaction of brivudine and capecitabine. Acta Oncol 48(4):631–633. https://doi.org/10.1080/02841860802660502CrossRefPubMed

Title: Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus
Authors: Larissa Henze
Christoph Buhl
Michael Sandherr
Oliver A. Cornely
Werner J. Heinz
Yascha Khodamoradi
Til Ramon Kiderlen
Philipp Koehler
Alrun Seidler
Rosanne Sprute
Martin Schmidt-Hieber
Marie von Lilienfeld-Toal
Publication date: 01-03-2022
Publisher: Springer Berlin Heidelberg
Keywords: Herpes Virus
Multiple Myeloma
Shingles
Human Alphaherpesvirus 3
Hematology
Published in: Annals of Hematology / Issue 3/2022
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-021-04746-y

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2022

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Aggressive NK-cell leukemia with hemophagocytosis in a Caucasian patient

ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies

A new case of Bicêtre hemoglobin in an adult male: clinical observations over a period of four years

Reduced bendamustine for elderly patients with follicular lymphoma

Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage